IgAN Treatment Market Worth Over $6B By 2032: Analyst Bearish On Povetacicept's Promising Role
Portfolio Pulse from Vandana Singh
RBC Capital Markets has initiated coverage on Alpine Immune Sciences Inc (NASDAQ:ALPN) with an Outperform rating and a price target of $19. The analysts perceive ALPN's lead candidate, povetacicept, as having a robust foundation for advancement in autoimmune indications. The IgAN treatment market, the primary focus of the RUBY-3 trial, is estimated to be worth over $6 billion by 2032. ALPN shares are up 5.73% at $12.37.

October 05, 2023 | 6:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital Markets has initiated coverage on Alpine Immune Sciences with an Outperform rating and a price target of $19. The company's lead candidate, povetacicept, is expected to advance in the autoimmune indications market.
The positive coverage from RBC Capital Markets, along with the promising prospects of the company's lead candidate, povetacicept, in the substantial IgAN treatment market, are likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100